WHO ICTRP trial
A suitable sedative dose of remifentanil for both mother and fetus in fetoscopic…
ACTRN12617000098336 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not recruiting
Key facts
| Trial ID | ACTRN12617000098336 |
|---|---|
| Public title | A suitable sedative dose of remifentanil for both mother and fetus in fetoscopic surgery |
| Scientific title | Suitable sedative dose of remifentanil in women undergoing fetoscopic laser photocoagulation for twin-twin transfusion syndrome |
| Primary sponsor | Department of anesthesiology, Shengjing hospital, China medical university |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Conditions | Pregant with twin-twin transfusion syndrome(TTTS) |
| Interventions | According to different rates of remifentanil administration, R1, R2 and R3 group are administered different dose rate of remifentanil (0.05micro-g/kg/min and 0.08micro-g/kg/min). Anesthesia induction of CSEA was done 5min before… |
| Registration date | Jan 17, 2017 |
| Target size | 30 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: